<DOC>
	<DOC>NCT01365520</DOC>
	<brief_summary>This trial is conducted in Asia and Europe. The aim of the trial is to investigate the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of a single dose of turoctocog alfa (NNC 0155-0000-0004 (N8)) in patients with haemophilia A. Participation in this trial is dependent on previous participation in trial NN7008-3543 (Part B) (NCT00840086).</brief_summary>
	<brief_title>A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects with the diagnosis of severe haemophilia A (factor VIII less than or equal to 1%) Body weight between 10 to 120 kg Subjects who have completed NN70083543 (Part B) or subjects participating in NN70083568 after completion of NN70083543 (NCT00840086) Known or suspected hypersensitivity to trial product(s) or related products Previous participation in this trial defined as withdrawal Planned surgery during the trial period (catheter, stents, ports, and dental extractions do not count as surgeries and will not exclude the subject) Any disease or condition which, according to the trial physician's judgement, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>